Krzysztof Kaczmarek

Dr. Krzysztof Kaczmarek

Institute of Organic Chemistry, Lodz University of Technology, Lodz, Poland
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
BJBojarska Joanna
Bojarska Joanna
Tsun-Thai ChaiTsun-Thai Chai
Tsun-Thai Chai
Sherif M. ElnagdySherif M. Elnagdy
Sherif M. Elnagdy
KKKrzysztof Kaczmarek
Krzysztof Kaczmarek
Istvan TothIstvan Toth
Istvan Toth
Peptides are fragments of proteins that carry out biological functions. They act as signaling entities via all domains of life and interfere with protein-protein interactions, which are indispensable in bio-processes. Short peptides include fundamental molecular information for a prelude to the symphony of life. They have aroused considerable interest due to their unique features and great promise in innovative bio-therapies. This work focusing on the current state-of-the-art short peptide-based therapeutical developments is the first global review written by researchers from all continents, as a celebration of 100 years of peptide therapeutics since the commencement of insulin therapy in the 1920s. Peptide “drugs” initially played only the role of hormone analogs to balance disorders. Nowadays, they achieve numerous biomedical tasks, can cross membranes, or reach intracellular targets. The role of peptides in bio-processes can hardly be mimicked by other chemical substances. The article is divided into independent sections, which are related to either the progress in short peptide-based theranostics or the problems posing challenge to bio-medicine. In particular, the SWOT analysis of short peptides, their relevance in therapies of diverse diseases, improvements in (bio)synthesis platforms, advanced nano-supramolecular technologies, aptamers, altered peptide ligands and in silico methodologies to overcome peptide limitations, modern smart bio-functional materials, vaccines, and drug/gene-targeted delivery systems are discussed.

1 February 2007 in Chemometrics and Intelligent Laboratory Systems
Verified
Journal Article
Closed access
Michal DaszykowskiMichal Daszykowski
Michal Daszykowski
SSSven Serneels
Sven Serneels
KKKrzysztof Kaczmarek
Krzysztof Kaczmarek
PEPiet Van Espen
Piet Van Espen
CCChristophe Croux
Christophe Croux
BWBeata Walczak
Beata Walczak

1 March 1988 in Biopolymers
Verified
Journal Article
Closed access
PDF file
EBE. Benedetti
E. Benedetti
VBV. Barone
V. Barone
ABA. Bavoso
A. Bavoso
BBB. Di Blasio
B. Di Blasio
FLF. Lelj
F. Lelj
ARA. Redlinski
A. Redlinski

3 March 2020 in Molecules
Verified
Journal Article
Open access
PDF file
BJBojarska Joanna
Bojarska Joanna
MRMilan Remko
Milan Remko
MBMartin Breza
Martin Breza
IMIzabela Madura
Izabela Madura
KKKrzysztof Kaczmarek
Krzysztof Kaczmarek
WWWojciech Wolf
Wojciech Wolf
The success of innovative drugs depends on an interdisciplinary and holistic approach to their design and development. The supramolecular architecture of living systems is controlled by non-covalent interactions to a very large extent. The latter are prone to extensive cooperation and like a virtuoso play a symphony of life. Thus, the design of effective ligands should be based on thorough knowledge on the interactions at either a molecular or high topological level. In this work, we emphasize the importance of supramolecular structure and ligand-based design keeping the potential of supramolecular H-bonding synthons in focus. In this respect, the relevance of supramolecular chemistry for advanced therapies is appreciated and undisputable. It has developed tools, such as Hirshfeld surface analysis, using a huge data on supramolecular interactions in over one million structures which are deposited in the Cambridge Structure Database (CSD). In particular, molecular interaction surfaces are useful for identification of macromolecular active sites followed by in silico docking experiments. Ornithine-derived compounds are a new, promising class of multi-targeting ligands for innovative therapeutics and cosmeceuticals. In this work, we present the synthesis together with the molecular and supramolecular structure of a novel ornithine derivative, namely N-α,N-δ)-dibenzoyl-(α)-hydroxymethylornithine, 1. It was investigated by modern experimental and in silico methods in detail. The incorporation of an aromatic system into the ornithine core induces stacking interactions, which are vital in biological processes. In particular, rare C=O…π intercontacts have been identified in 1. Supramolecular interactions were analyzed in all structures of ornithine derivatives deposited in the CSD. The influence of substituent was assessed by the Hirshfeld surface analysis. It revealed that the crystal packing is stabilized mainly by H…O, O…H, C…H, Cl (Br, F)…H and O…O interactions. Additionally, π…π, C-H…π and N-O…π interactions were also observed. All relevant H-bond energies were calculated using the Lippincott and Schroeder H-bond model. A library of synthons is provided. In addition, the large synthons (Long-Range Synthon Aufbau Module) were considered. The DFT optimization either in vacuo or in solutio yields very similar molecular species. The major difference with the relevant crystal structure was related to the conformation of terminal benzoyl C15-C20 ring. Furthermore, in silico prediction of the extensive physicochemical ADME profile (absorption, distribution, metabolism and excretion) related to the drug-likeness and medicinal chemistry friendliness revealed that a novel ornithine derivative 1 has the potential to be a new drug candidate. It has shown good in silico absorption and very low toxicity.

22 September 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
QZQirui Zhang
Qirui Zhang
RNRonald J. Nachman
Ronald J. Nachman
KKKrzysztof Kaczmarek
Krzysztof Kaczmarek
JZJanusz Zabrocki
Janusz Zabrocki
DDDavid L. Denlinger
David L. Denlinger
The dormant state known as diapause is widely exploited by insects to circumvent winter and other adverse seasons. For an insect to survive, feed, and reproduce at the appropriate time of year requires fine coordination of the timing of entry into and exit from diapause. One of the hormones that regulates diapause in moths is the 24-aa neuropeptide, diapause hormone (DH). Among members of the Helicoverpa / Heliothis complex of agricultural pests, DH prompts the termination of pupal diapause. Based on the structure of DH, we designed several agonists that are much more active than DH in breaking diapause. One such agonist that we describe also prevents the entry into pupal diapause when administered to larvae that are environmentally programmed for diapause. In addition, we used the unique antagonist development strategy of incorporating a dihydroimidazole (“Jones”) trans -Proline mimetic motif into one of our DH agonists, thereby converting the agonist into a DH antagonist that blocks the termination of diapause. These results suggest potential for using such agents or next-generation derivatives for derailing the success of overwintering in pest species.

1 March 1988 in Biopolymers
Verified
Journal Article
Closed access
PDF file
CTC. Toniolo
C. Toniolo
GBG. M. Bonora
G. M. Bonora
ABA. Bavoso
A. Bavoso
EBE. Benedetti
E. Benedetti
BBB. Di Blasio
B. Di Blasio
ARA. Redlinski
A. Redlinski